Traws Pharma shares surge 20.06% after-hours following Q3 results with cost cuts, IP acquisitions, and antiviral drug development progress.

Traws Pharma surged 20.06% in after-hours trading following the release of its Q3 2025 financial results, which highlighted significant cost reductions, acquisition of intellectual property assets, and progress in Phase 2 trials for antiviral therapies targeting COVID-19 and influenza. The company reported a narrowed net loss compared to the prior year and outlined strategic shifts toward antiviral programs, underscoring potential in high-demand markets. Analysts cited a Buy rating with a $6.00 price target, aligning with the stock’s upward movement. While technical indicators remain bearish, the news emphasized operational improvements and therapeutic advancements, likely driving investor optimism despite broader market skepticism.